ProMIS Neurosciences Inc PMN

U.S. FDA staff says effectiveness data to support approval .

[Mole101]

Biogen up 26% ...

U.S. FDA staff says effectiveness data to support approval of Biogen Alzheimer's drug

Wed, November 4, 2020, 7:20 AM PST ·1 min read

Nov 4 (Reuters) - Biogen Inc's experimental Alzheimer's disease drug was found effective enough in a large trial to support approval, a U.S. Food and Drug Administration panel said on Wednesday, boosting the chances of a swift approval of the drug.

As a next step to a regulatory approval, the drug will be reviewed by FDA's independent experts in a meeting on Friday that will make recommendations to the agency.

U.S. Food and Drug Administration's independent experts will consider the remarks in a meeting on Friday, before making their recommendations to the agency.

A final decision on the drug, jointly developed with Japan's Eisai Co Ltd, is due by March 2021. (Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

[M101]

So the market says it's a sure thing now, and thanks to the brilliant strategy of Gene and Elliot the only upside for PMN is that this doesn't cause a sell off. 

[Annayya]

Good thing I didn't sell any shares but they seriously should have done the PP well above the 20 cents. Let's hope we close over 18 to 20 cents today and close the PP today with all the demand.